Project Description

Adjutec Pharma

Adjutec Pharma’s vision is to develop and provide novel antibiotic resistance breakers in order to retain efficacy and facilitate reduced use of antibiotics. Its lead products are two β-lactamase inhibitors (BLI) targeting metallo-β-lactamase and serine-β -lactamases, APC148 and APC247 respectively. They have demonstrated in-vitro and in-vivo efficacy in large panels of multidrug-resistant isolates. The chemical synthesis route is scalable, and preliminary tests indicate a favorable toxicity profile.

The third pipeline product targets resistant tuberculosis (TB-MDR) and has already shown better result in-vitro compared to the latest drug registered on the market.

All APIs are secured under company patents and the Adjutec has attracted €5mill public and private funding to drive preclinical development.

Adjutec is building an experienced management team consisting of:

  • CEO Bjørn Klem, M.Sc. Pharmacy Oslo with previous leading positions in R&D of Norwegian biotechs and CEO of Oslo Cancer Cluster Incubator.
  • CSO Pål Rongved, Ph.D. in Chemistry Oslo and IPR expert. Founder of Adjutec with previous leading positions in R&D at GE HealthCare. Professor at University of Oslo.
  • CTO Ragnar Hovland, Ph.D. in Medicinal chemistry Oslo. Previous leading CMC positions of international pharma and Norwegian biotechs.
  • CRDO Bjørg Bolstad, M.Sc. Oslo. Previous leading positions in clinical R&D of Norwegian biotechs. Presently Senior advisor to Norwegian Medicinal Agency and Norwegian representative at CHMP at EMA.

Company details

More companies